Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

Group (NCIC CTG) based at Queen's University in Kingston, Ontario. The trial was further supported by an unrestricted grant from Sanofi-Aventis.

Webcast and Conference Call Today

OncoGenex will hold a live webcast and conference call of presentations made at a Company hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) today, May 30, 2009. The webcast will begin at 7:10 p.m. EDT.

During the reception, OncoGenex management and guest speakers will provide a comprehensive review of the final results of the randomized Phase 2 trial presented at the ASCO Annual Meeting, as well as discuss the treatment landscape and the relevance of clinical trial endpoints for prostate cancer.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-627-6544 (U.S. & Canada) or 719-325-4857 (International). A webcast replay will be available approximately two hours after the call and will be archived at www.oncogenex.com.

About OGX-011

OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance and is currently being evaluated in Phase 2 clinical trials in prostate, lung and breast cancer. At the 2009 American Urological Association Annual Meeting, OncoGenex reported Phase 2 data with OGX-011 in combination with second-line treatment of metastatic castrate resistant prostate cancer showing better than expected survival results, reductions in levels of clusterin, durable reductions in pain, and a decline in PSA, a protein that is often elevated in patients with prostate cancer.

Based on clinical results to date, OncoGenex intends to conduct Phase 3 registration trials
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... DALLAS , July 10, 2014  Kainos Capital, ... consumer brands, today announced that it has acquired the ... stake in the business. Terms of the transaction were ... loss and meal replacement business that markets ready-to-drink shakes, ... North America and in the ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Monogram announces availability of HERmark and HER1 and HER3 ... Assays ... June 2 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... on HERmark(TM),the company,s novel oncology assay, as a means ...
... (TSH),Canada,s largest urban community hospital, has selected Chyma(TM) ... The,implementation of Chyma(TM) for their team of more ... departments at the two hospital campuses and will,soon ... "Chyma(TM) reflects the commitment of the Scarborough ...
... 2 The following release was,issued today by Thomas P. ... the New York State Common Retirement Fund, the Lead Plaintiff,in ... UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA ... MCK ) SECURITIES LITIGATION, Master File No. 99-CV-20743 ...
Cached Biology Technology:Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 2Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 3Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 4Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 5Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 6Canada's Largest Urban Community Hospital Chooses Chyma(TM) On-Call Physician Scheduling Technology 2Notice of Initial Distribution of Net Settlement Funds 2Notice of Initial Distribution of Net Settlement Funds 3
(Date:7/11/2014)... Conservation Society shows that no-take zones in Belize ... as lobster, conch, and fish recover from overfishing, ... , The reporttitled "Review of the Benefits of ... from no-take areas around the world. The report ... expert in marine protected areas and fisheries management. ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... eastern New South Wales, Australia when NASA,s Aqua satellite ... on July 11 (12:35 p.m. local time/11:35 p.m. EDT ... South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) ... and spotted smoke (light brown) from various fires. Actively ... in red. , The New South Wales, Australia Government ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... find your location, the brain has an internal system for ... surroundings. A new study from researchers at Princeton University ... study, published in the journal Nature , indicates that ... activity up and down by working together in a collective ...
... , , , , , , ... AUDIO: Kathryn E. Henderson, PhD, Director of School and Community Initiatives at the Yale Rudd Center, talks about the first ... for more information. , , , , ... , , , , , , , ...
... 6, 2013) -- Working with a multidisciplinary consortium of ... critical information to identify CALHM1, a channel in the ... in the process of sweet, bitter, and umami (savory) ... reach the tongue, they activate taste receptors in specialized ...
Cached Biology News:Researchers discover workings of brain's 'GPS system' 2Stronger support needed for healthy beverage practices in child care 2Stronger support needed for healthy beverage practices in child care 3Stronger support needed for healthy beverage practices in child care 4Monell scientists help identify a missing link in taste perception 2
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Proliferin (C-14)...
... your ValveBank system! Program your valve ... computer using graphic 'click-and-drag' timebars. Save and ... program listings, then download your programs into ... EasyCode is used for programming before -- ...
Biology Products: